Mirum Pharmaceuticals Inc

NASDAQ:MIRM  
17.20
+0.16 (+0.94%)
Products

Takeda Pharmaceutical Co Ltd Partners With Takeda To Develop Maralixibat For Rare Pediatric Liver Diseases In Japan

Published: 09/21/2021 12:34 GMT
Mirum Pharmaceuticals Inc (MIRM) - Mirum Pharmaceuticals and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan.
Mirum Pharmaceuticals Inc - Takeda Will Be Responsible for Regulatory Approval and Commercialization of Maralixibat in Japan.
Mirum Pharmaceuticals Inc - Takeda Will Also Be Responsible for Development, Including Conducting Clinical Studies in Cholestatic Indications.